1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Towa Follows Suit With Sawai To Steal Japanese Share From Nichi-Iko

Nichi-Iko And Kobayashi Kako Suffering With Domestic Supply Problems

 
• By Dean Rudge

Japanese player Towa Pharmaceutical joined Sawai in capitalizing on Nichi-Iko’s misery by taking market share from its rival, as it ran factories at full capacity and plotted for further expansion.

competition
Towa Matched Sawai During Q1 • Source: Alamy

Towa Pharmaceutical Co Ltd mirrored Japanese rival Sawai Pharmaceutical Co., Ltd. during its financial first quarter ended 30 June 2021, benefitting from domestic supply stoppages of products from other local generics manufacturers while struggling to make inroads with its nascent operations overseas, namely the US.

The Osaka-based firm’s net sales climbed by 13.3% to ¥42

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.